Skip to main content
PRGO
NYSE Life Sciences

Perrigo Cuts 2026 Core EPS Outlook to $2.15-$2.35 on Soft Europe, Flags $275M-$375M Infant Formula Impairment

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$16.15
Mkt Cap
$2.179B
52W Low
$9.225
52W High
$20.65
52W Position info
75% above low
Off High info
22% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PRGO sits 75% above its 52-week low of $9.225.

Summary

Perrigo's Q3 swung to a $(0.10) reported loss, and management cut full-year Core adjusted EPS guidance to $2.15-$2.35 from $2.25-$2.55, citing softer retailer orders and weak Europe. The Infant Formula sale will also trigger a $275M-$375M impairment in Q4.


Key Events · Earnings and Guidance · PRGO

  • Q3 Swings to Reported Loss

    Reported diluted EPS was $(0.10) versus $0.09 a year ago; All In adjusted EPS fell 25.0% to $0.60 from $0.80. Net sales declined 5.2% to $989 million.

  • Full-Year Guidance Cut

    Core adjusted EPS outlook lowered to $2.15-$2.35 from $2.25-$2.55, and Core organic net sales growth now seen at (3.8)% to (2.7)% versus the prior (3.0)% to 1.0%.

  • Infant Formula Impairment Ahead

    The pending divestiture to MeridianMade for up to $175 million ($40 million upfront cash) is expected to produce a $275.0 million to $375.0 million impairment loss in Q4 2026 when measured as held for sale.

  • Leverage Still Elevated

    Total debt was $3.3 billion against $437 million of cash at September 26, 2026, with net leverage guided to approximately 4.0 times adjusted EBITDA.


Analysis · PRGO · Life Sciences

Sales for the quarter were roughly in line ($989M vs $987.2M consensus), but the profit picture deteriorated: reported diluted EPS swung to a $(0.10) loss from $0.09, and All In adjusted EPS fell 25% to $0.60. More important is the reset underneath. Management cut Core adjusted EPS guidance to $2.15-$2.35 from $2.25-$2.55 and now expects Core organic sales to decline 3.8%-2.7% versus a prior range that reached flat-to-up. The causes are named: more cautious retailer inventory positioning ahead of cough and cold season, and continued European consumer weakness. Layered on top is a $275M-$375M impairment on the Infant Formula business when it is marked held-for-sale in Q4, a real hit to book equity even though it is non-cash. Against $3.3B of total debt and roughly 4.0x net leverage, the $40M upfront cash from that divestiture does little to deleverage on its own.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRGO was trading at $16.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.23 to $20.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRGO - Latest Insights

PRGO
Nov 04, 2026, 12:54 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.47
Real-time Price: $16.04 info
Change: -$0.425 (-3%) info
Market Cap: $2.226B info
PRGO
Nov 04, 2026, 6:41 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $16.15
Real-time Price: $16.04 info
Change: -$0.110 (-0.68%) info
Market Cap: $2.226B info
PRGO
Nov 04, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.70
Real-time Price: $16.04 info
Change: +$0.340 (+2%) info
Market Cap: $2.226B info
PRGO
Oct 29, 2026, 9:01 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.95
Real-time Price: $16.04 info
Change: +$0.090 (+0.56%) info
Market Cap: $2.226B info
PRGO
Oct 09, 2026, 4:17 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $15.09
Real-time Price: $16.04 info
Change: +$0.950 (+6%) info
Market Cap: $2.226B info